Literature DB >> 10516040

Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes.

A Lieber1, D S Steinwaerder, C A Carlson, M A Kay.   

Abstract

Recently, we demonstrated that inverted repeat sequences inserted into first-generation adenovirus (Ad) vector genomes mediate precise genomic rearrangements resulting in vector genomes devoid of all viral genes that are efficiently packaged into functional Ad capsids. As a specific application of this finding, we generated adenovirus-adeno-associated virus (AAV) hybrid vectors, first-generation Ad vectors containing AAV inverted terminal repeat sequences (ITRs) flanking a reporter gene cassette inserted into the E1 region. We hypothesized that the AAV ITRs present within the hybrid vector genome could mediate the formation of rearranged vector genomes (DeltaAd.AAV) and stimulate transgene integration. We demonstrate here that DeltaAd.AAV vectors are efficiently generated as by-products of first-generation adenovirus-AAV vector amplification. DeltaAd.AAV genomes contain only the transgene flanked by AAV ITRs, Ad packaging signals, and Ad ITRs. DeltaAd.AAV vectors can be produced at a high titer and purity. In vitro transduction properties of these deleted hybrid vectors were evaluated in direct comparison with first-generation Ad and recombinant AAV vectors (rAAVs). The DeltaAd.AAV hybrid vector stably transduced cultured cells with efficiencies comparable to rAAV. Since cells transduced with DeltaAd.AAV did not express cytotoxic viral proteins, hybrid viruses could be applied at very high multiplicities of infection to increase transduction rates. Southern analysis and pulsed-field gel electrophoresis suggested that DeltaAd.AAV integrated randomly as head-to-tail tandems into the host cell genome. The presence of two intact AAV ITRs was crucial for the production of hybrid vectors and for transgene integration. DeltaAd.AAV vectors, which are straightforward in their production, represent a promising tool for stable gene transfer in vitro and in vivo.

Entities:  

Mesh:

Year:  1999        PMID: 10516040      PMCID: PMC112966     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  Site-specific integration mediated by a hybrid adenovirus/adeno-associated virus vector.

Authors:  A Recchia; R J Parks; S Lamartina; C Toniatti; L Pieroni; F Palombo; G Ciliberto; F L Graham; R Cortese; N La Monica; S Colloca
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

Review 2.  Use of adeno-associated virus as a general transduction vector for mammalian cells.

Authors:  N Muzyczka
Journal:  Curr Top Microbiol Immunol       Date:  1992       Impact factor: 4.291

3.  Origin of adeno-associated virus DNA replication is a target of carcinogen-inducible DNA amplification.

Authors:  A O Yalkinoglu; H Zentgraf; U Hübscher
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

4.  Adenoviral preterminal protein stabilizes mini-adenoviral genomes in vitro and in vivo.

Authors:  A Lieber; C Y He; M A Kay
Journal:  Nat Biotechnol       Date:  1997-12       Impact factor: 54.908

Review 5.  Adenoviral DNA integration and changes in DNA methylation patterns: a different view of insertional mutagenesis.

Authors:  W Doerfler
Journal:  Prog Nucleic Acid Res Mol Biol       Date:  1993

6.  Palindromic adenovirus type 5-simian virus 40 hybrid.

Authors:  Y Gluzman; K Van Doren
Journal:  J Virol       Date:  1983-01       Impact factor: 5.103

7.  Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver.

Authors:  H Nakai; Y Iwaki; M A Kay; L B Couto
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

8.  Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.

Authors:  R J Samulski; L S Chang; T Shenk
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

9.  Adeno-associated virus vectors preferentially transduce cells in S phase.

Authors:  D W Russell; A D Miller; I E Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

10.  SK HEP-1: a human cell line of endothelial origin.

Authors:  S C Heffelfinger; H H Hawkins; J Barrish; L Taylor; G J Darlington
Journal:  In Vitro Cell Dev Biol       Date:  1992-02
View more
  19 in total

1.  Generation of adenovirus vectors devoid of all viral genes by recombination between inverted repeats.

Authors:  D S Steinwaerder; C A Carlson; A Lieber
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector.

Authors:  D M Shayakhmetov; T Papayannopoulou; G Stamatoyannopoulos; A Lieber
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

Review 3.  Hematopoietic stem cell gene therapy.

Authors:  David W Emery; Tamon Nishino; Ken Murata; Michalis Fragkos; George Stamatoyannopoulos
Journal:  Int J Hematol       Date:  2002-04       Impact factor: 2.490

4.  Genome size and structure determine efficiency of postinternalization steps and gene transfer of capsid-modified adenovirus vectors in a cell-type-specific manner.

Authors:  Dmitry M Shayakhmetov; Zong-Yi Li; Anuj Gaggar; Helen Gharwan; Vladimir Ternovoi; Volker Sandig; André Lieber
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  Gene therapy to the kidney using viral vectors.

Authors:  Talha Akbulut; Frank Park
Journal:  Paidiatrike       Date:  2008

Review 6.  Targeting site-specific chromosome integration.

Authors:  Patricia Nuno-Gonzalez; Hsu Chao; Kazuhiro Oka
Journal:  Acta Biochim Pol       Date:  2005-06-03       Impact factor: 2.149

7.  A rapid protocol for construction and production of high-capacity adenoviral vectors.

Authors:  Lorenz Jager; Martin A Hausl; Christina Rauschhuber; Nicola M Wolf; Mark A Kay; Anja Ehrhardt
Journal:  Nat Protoc       Date:  2009       Impact factor: 13.491

Review 8.  Gene therapy for Fabry disease.

Authors:  C Siatskas; J A Medin
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

Review 9.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

10.  A capsid-modified helper-dependent adenovirus vector containing the beta-globin locus control region displays a nonrandom integration pattern and allows stable, erythroid-specific gene expression.

Authors:  Hongjie Wang; Dmitry M Shayakhmetov; Tobias Leege; Michael Harkey; Qiliang Li; Thalia Papayannopoulou; George Stamatoyannopolous; André Lieber
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.